Idera Pharmaceuticals, Inc. IDRA today announced the receipt of
verbal notification from the Food and Drug Administration that the
company may proceed with a Phase 2 clinical trial of IMO-3100 in patients with
psoriasis based on a trial protocol submitted by the company in October 2011.
IMO-3100 is a dual antagonist of Toll-like receptor (TLR) 7 and TLR9 and is in
clinical development as a potential therapy for autoimmune and inflammatory
diseases.
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in